Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by capebretongirlon Apr 09, 2021 5:44pm
165 Views
Post# 32971306

Next Week

Next WeekWe need some momentum to turn this around as investor sentiment is not with us and lets face it - shorters have had a field day with every day seeing red. When we were at $1.57 the momentum was there on anticipation of the Aristotle and Q4 rollout - it was a perfect scenario, however that flopped and here we are.  One thing we have learned is that exchanging views on SH doesn't change anythng - the only catalyst to turn this around is the prospect of an NR next week - Tripp mentioned during the CC that they would be coming shortly so he needs to deliver, bearing in mind he had said this before and we waited almost 3 months prior to Aristotle. In future, I think everyone would like to see if nothing else, status NRs as silence just doesn't work.
<< Previous
Bullboard Posts
Next >>